Standout Papers
- Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials (2023)
- Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials (2024)
- Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis (2016)
- Chronic Rhinosinusitis with Nasal Polyps and Asthma (2020)
- Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis (2022)
Citation Impact
1 by Nobel laureates 5 from Science/Nature 60 standout
Citing Papers
Incident allergic diseases in post-COVID-19 condition: multinational cohort studies from South Korea, Japan and the UK
2024 Standout
Eosinophil Depletion with Benralizumab for Eosinophilic Esophagitis
2024 Standout
Works of Leda Mannent being referenced
Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
2023
Dupilumab Improves Clinical and Histologic Aspects of Disease in Adult and Adolescent Patients With Eosinophilic Esophagitis at Week 24: Results from Part B of the 3-Part LIBERTY EoE TREET Study
2022
Author Peers
| Author | Otorhinolaryngology | Physiology | IA | Last Decade | Papers | Cites |
|---|---|---|---|---|---|---|
| Leda Mannent | 1242 | 1311 | 1387 | 69 | 2.4k | |
| Betina Biolatto | 2 | 11 | 800 | |||
| Juan Carlos Fasciolo | 51 | 1 | 17 | 232 | ||
| Julija Baranova | 7 | 321 | ||||
| E. Tánczos | 1 | 13 | 169 | 12 | 534 | |
| Lorenz Welker | 14 | 241 |
All Works
Loading papers...